-

Marc Princen appointed new Global CEO for Mundipharma

CAMBRIDGE, England--(BUSINESS WIRE)--FOR MEDICAL BUSINESS/TRADE MEDIA ONLY

Mundipharma announced today that Marc Princen has joined the Mundipharma network of independently associated companies as the Global Chief Executive Officer, effective June 1, 2020. In his new role, Princen will be responsible for all Mundipharma strategic and operational matters globally, focusing on seamless execution of the 2020-2023 Business Plan.

Speaking of the appointment, Jacques Theurillat, Chairman, said “Marc is a highly proven pharmaceutical executive with a strong track record at leading pharma companies such as Schering-Plough, Merck & Co, Takeda and Allergan. He is widely recognised for his expertise in business change and transformation and joins us at an important moment as we continue our evolution as an organization. I wish him every success in his role with us.”

Marc is joining Mundipharma from Allergan International, where he was the President and EVP, International Business. He brings more than 30 years cross-functional experience in the pharmaceutical Industry with expertise spanning commercial, marketing, business development and management. Marc holds a Bachelor in Physiotherapy degree from Katholieke Universiteit in Leuven, Belgium.

“I am proud and delighted to be joining Mundipharma at this pivotal time,” Princen said. “I see a genuine opportunity to help build a new and exciting future for the organisation as it continues on its transformation journey.”

-Ends-

Notes to editors:

About the Mundipharma network

Mundipharma is a global (ex-US) network of privately-owned independent associated companies with a presence across Africa, Asia Pacific, Europe, Canada, Latin America and the Middle East.

We are dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as Anti-Infectives, Biosimilars, CNS, Diabetes, Oncology & supportive care, Ophthalmology, Pain Management, Respiratory and Consumer Healthcare.

For further information by geographic region please go to www.mundipharma.com (Europe); http://purdue.ca/en/ (Canada) and www.mundipharma.com.sg (other ex-US markets).

Contacts

For further information please contact:
Helen Rae
helenrae@makarahealth.com
T: +44 (0) 23 81 247 327

Rob Gallo
rob.gallo@mundipharma.com
T: +44 (0) 7773 009578

Mundipharma


Release Versions

Contacts

For further information please contact:
Helen Rae
helenrae@makarahealth.com
T: +44 (0) 23 81 247 327

Rob Gallo
rob.gallo@mundipharma.com
T: +44 (0) 7773 009578

More News From Mundipharma

Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)

CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma today announced completion of patient enrolment for the ongoing, global Phase III ReSPECT trial evaluating REZZAYO® (rezafungin). The ReSPECT trial is a global, randomised, double-blind, controlled, pivotal Phase 3 trial of rezafungin versus the standard antimicrobial regimen to prevent invasive fungal disease due to Candida, Aspergillus and Pneumocystis in subjects undergoing allogeneic blood and marrow transplantation. “Completing patient enrol...

New global guideline published on managing fungal infections caused by Candida

CAMBRIDGE, England--(BUSINESS WIRE)--A new global guideline for the diagnosis and treatment of Candida infections was recently published in Lancet Infectious Diseases1. This guideline sets out new standards for managing fungal infections, which affect millions of people worldwide every year. The global guideline was developed by a team of more than 100 experts spanning 35 countries and led by Professor Dr. Oliver A. Cornely and Dr. Rosanne Sprute from University Hospital Cologne. One year follo...

Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafungin is a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3...
Back to Newsroom